Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22082472 | 0.84 | ALDH1A1 (0.35) | ALDH1A1HTT | |
| SCHEMBL22034572 | 0.83 | BBOX1 (0.47) | BBOX1ALDH1A1HTTSMN1; SMN2LMNA | |
| Bromide SCHEMBL22034523 | 0.82 | HTT (0.35) | ALDH1A1HTT | |
| SCHEMBL19762864 | 0.81 | BBOX1 (0.44) | BBOX1HTTSMN1; SMN2LMNARAB9A | |
| Bromide SCHEMBL23877773 | 0.80 | BBOX1 (0.43) | BBOX1HTTSMN1; SMN2LMNARAB9A | |
| SCHEMBL19762855 | 0.79 | BBOX1 (0.42) | BBOX1HTTSMN1; SMN2LMNARAB9A | |
| SCHEMBL22034441 | 0.79 | BBOX1 (0.39) | BBOX1HTTSMN1; SMN2LMNARAB9A | |
| Bromide SCHEMBL23877775 | 0.78 | BBOX1 (0.41) | BBOX1ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL22034488 | 0.77 | BBOX1 (0.38) | BBOX1HTTSMN1; SMN2LMNARAB9A | |
| SCHEMBL19762880 | 0.77 | HTT (0.49) | BBOX1HTTSMN1; SMN2LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| CN-109640967-B | Method for inhibiting conversion of choline to Trimethylamine (TMA) | 宝洁公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11246844-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2022-02-15 | — | — | US | disclosed |
| US-11246844-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3478276-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20180000754-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246844-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | HNMT, CHAT, BHMT | BBOX1 157/4885ALDH1A1 1761/4885HTT 4035/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | BBOX1 413/4885ALDH1A1 1296/4885HTT 1960/4885 |
| US-20180000754-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | HNMT, CHAT, BHMT | BBOX1 157/4885ALDH1A1 1761/4885HTT 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.